Novavax, Inc. (Nasdaq: NVAX), a US-based biotechnology company, announced on Friday that it has received expanded emergency use authorisation (EUA) from the Taiwan Food and Drug Administration (TFDA) for its Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 to 17.
The approval is based on data from the ongoing paediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 to 17 years across 75 sites in the United States to assess the safety and effectiveness of the product.
Preliminary safety data from the paediatric expansion indicated the vaccine to be generally well-tolerated.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine